Galderma Receives FDA Approval of Novel Treatment Option for Rosacea Patients
Soolantra® (ivermectin) Cream, 1% found to be well tolerated with powerful results seen as early as two weeks
FORT WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) approved Soolantra® (ivermectin) Cream, 1% for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. Rosacea is a common, but often misunderstood, skin disorder affecting 16 million Americans, predominantly women, ages 30 and older. Although the cause of rosacea is unknown, research suggests that there are multiple triggers for the inflammation associated with the condition, including sun, alcohol, spicy food and exercise. Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are normal inhabitants of everyone’s skin, but may appear in greater numbers on the faces of people with rosacea.
[url]http://www.businesswire.com/news/hom...acea#.VJoFDAAA[/url]